首页 > 最新文献

Biology of the neonate最新文献

英文 中文
Cortical excitatory amino acid release and cell function during hypotension in near-term born lambs. 初生羔羊低血压时皮质兴奋性氨基酸释放和细胞功能。
Pub Date : 2006-01-01 Epub Date: 2006-03-30 DOI: 10.1159/000092450
Sandra van Os, Wim Ruitenbeek, Jeroen Hopman, John Klaessens, Margot van de Bor

Background: Energy failure due to insufficient cerebral O2-supply leads to excess accumulation of calcium ions in presynaptic neurons, followed by excess release of excitatory amino acids, which are potent neurotoxins, into the synaptic cleft.

Aim: To investigate whether electrocortical brain activity (ECBA) can provide an adequate measure for excitatory amino acid release due to hemorrhagic hypotension.

Methods: Ten near-term lambs were delivered at 127 days of gestation (term: 147 days). After a stabilization period, hypotension was induced by stepwise withdrawal of blood. Cerebral microdialysis was used to measure the concentrations of glutamate and aspartate.

Results: During hypotension, mean arterial blood pressure, cerebral O2-supply and ECBA decreased and the extracellular concentration of glutamate increased significantly. ECBA was significantly related to glutamate (R2: 0.67, p < 0.001) and aspartate (R2: 0.57, p < 0.001) concentrations.

Conclusion: The extracellular release of glutamate and aspartate in the cerebral cortex increases after hemorrhagic hypotension in near-term born lambs. The extracellular overflow of glutamate and aspartate were significantly inversely related to ECBA.

背景:脑o2供应不足导致的能量衰竭导致突触前神经元钙离子过量积累,随后兴奋性氨基酸过量释放,这是一种强效神经毒素,进入突触间隙。目的:探讨脑皮层电活动(ECBA)能否为出血性低血压引起的兴奋性氨基酸释放提供充分的测量方法。方法:选取妊娠127天(足月147天)分娩的近期羔羊10只。经过一段稳定期后,逐步抽血诱导低血压。脑微透析法测定谷氨酸和天冬氨酸浓度。结果:低血压时,平均动脉血压、脑o2供应和ECBA下降,细胞外谷氨酸浓度明显升高。ECBA与谷氨酸(R2: 0.67, p < 0.001)和天冬氨酸(R2: 0.57, p < 0.001)浓度显著相关。结论:初生羔羊出血性低血压后,大脑皮层谷氨酸和天冬氨酸的细胞外释放增加。谷氨酸和天冬氨酸的细胞外溢出与ECBA呈显著负相关。
{"title":"Cortical excitatory amino acid release and cell function during hypotension in near-term born lambs.","authors":"Sandra van Os,&nbsp;Wim Ruitenbeek,&nbsp;Jeroen Hopman,&nbsp;John Klaessens,&nbsp;Margot van de Bor","doi":"10.1159/000092450","DOIUrl":"https://doi.org/10.1159/000092450","url":null,"abstract":"<p><strong>Background: </strong>Energy failure due to insufficient cerebral O2-supply leads to excess accumulation of calcium ions in presynaptic neurons, followed by excess release of excitatory amino acids, which are potent neurotoxins, into the synaptic cleft.</p><p><strong>Aim: </strong>To investigate whether electrocortical brain activity (ECBA) can provide an adequate measure for excitatory amino acid release due to hemorrhagic hypotension.</p><p><strong>Methods: </strong>Ten near-term lambs were delivered at 127 days of gestation (term: 147 days). After a stabilization period, hypotension was induced by stepwise withdrawal of blood. Cerebral microdialysis was used to measure the concentrations of glutamate and aspartate.</p><p><strong>Results: </strong>During hypotension, mean arterial blood pressure, cerebral O2-supply and ECBA decreased and the extracellular concentration of glutamate increased significantly. ECBA was significantly related to glutamate (R2: 0.67, p < 0.001) and aspartate (R2: 0.57, p < 0.001) concentrations.</p><p><strong>Conclusion: </strong>The extracellular release of glutamate and aspartate in the cerebral cortex increases after hemorrhagic hypotension in near-term born lambs. The extracellular overflow of glutamate and aspartate were significantly inversely related to ECBA.</p>","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"90 2","pages":"128-34"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000092450","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25944620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Relevance of tenascin-C and matrix metalloproteinases in vascular abnormalities in murine hypoplastic lungs. tenascin-C和基质金属蛋白酶与小鼠发育不全肺血管异常的相关性。
Pub Date : 2006-01-01 Epub Date: 2006-05-12 DOI: 10.1159/000093308
Mala R Chinoy, Shane A Miller

Background: Tenascin-C (TN-C), an extracellular matrix glycoprotein, is crucial to cell-migration, proliferation, apoptosis and remodeling of tissues, with a potential role in pathobiology of pulmonary hypertension. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are crucial to the integrity of the extracellular matrix. TN-C and MMPs are counter-regulatory molecules, which influence the vascular integrity through modulations of elastin. We have a murine model of pulmonary hypoplasia with coexistent diaphragmatic hernia, vascular abnormalities and excessive arterial smooth muscle cell (SMC) proliferation.

Objectives: Our objective was to investigate modulations of TN-C and MMPs in hypoplastic lungs and their possible contribution to the observed pulmonary vascular abnormalities.

Methods: We addressed our objectives by pursing immunoblotting and immunohistochemistry and zymography/reverse zymography to assess the alterations in activities of MMPs and their inhibitors.

Results: We observed significant down-regulation of MMP-9 activity in hypoplastic lungs at the later fetal developmental stages, whereas MMP-2 activity assessed by gelatin zymography remained unaltered. Reverse zymography revealed up-regulation of activities of TIMP-1, -2, -3 and -4 in hypoplastic lungs during later fetal development, with pronounced increases in TIMP-3 and -4 activities. Furthermore, immunoblot analyses and immunohistochemistry revealed that TN-C protein was down-regulated in developing hypoplastic lungs, compared to normal lungs.

Conclusions: (1)TN-C is known to inhibit vascular SMC proliferation. But, decrease in TN-C in hypoplastic lungs may support the observed arterial SMC proliferation. (2) Our studies showed that in hypoplastic lungs the SMC apoptosis is not affected, thus suggesting that SMC proliferation and apoptosis may be two separate processes in pulmonary hypoplasia with coexistent diaphragmatic hernia. Together, our data showed an imbalance in the extracellular matrix proteins, which may contribute to the pulmonary vascular abnormalities.

背景:Tenascin-C(TN-C)是一种细胞外基质糖蛋白,对细胞迁移、增殖、凋亡和组织重塑至关重要,可能在肺动脉高压的病理生物学中发挥作用。基质金属蛋白酶(MMPs)和组织金属蛋白酶抑制剂(TIMPs)对细胞外基质的完整性至关重要。TN-C 和 MMPs 是反调节分子,它们通过调节弹性蛋白影响血管的完整性。我们有一个肺发育不全的小鼠模型,该模型同时伴有膈疝、血管异常和动脉平滑肌细胞(SMC)过度增殖:我们的目的是研究肺发育不全模型中 TN-C 和 MMPs 的变化,以及它们对观察到的肺血管异常可能起到的作用:我们通过免疫印迹、免疫组织化学和酶谱/反酶谱来评估 MMPs 及其抑制剂活性的变化,从而实现我们的目标:结果:我们观察到,在胎儿发育后期,发育不全肺中的MMP-9活性明显下调,而明胶酶谱法评估的MMP-2活性则保持不变。反向酶谱分析显示,在胎儿发育后期,发育不全的肺中 TIMP-1、-2、-3 和 -4 活性上调,其中 TIMP-3 和 -4 活性明显增加。此外,免疫印迹分析和免疫组化显示,与正常肺相比,发育不全肺中的 TN-C 蛋白下调。结论:(1)众所周知,TN-C 可抑制血管 SMC 的增殖,但发育不全肺中 TN-C 蛋白的减少可能支持所观察到的动脉 SMC 增殖。(2)我们的研究表明,在肺发育不全中,SMC的凋亡并未受到影响,这表明在肺发育不全与膈疝同时存在的情况下,SMC的增殖和凋亡可能是两个独立的过程。总之,我们的数据显示细胞外基质蛋白失衡,这可能是导致肺血管异常的原因之一。
{"title":"Relevance of tenascin-C and matrix metalloproteinases in vascular abnormalities in murine hypoplastic lungs.","authors":"Mala R Chinoy, Shane A Miller","doi":"10.1159/000093308","DOIUrl":"10.1159/000093308","url":null,"abstract":"<p><strong>Background: </strong>Tenascin-C (TN-C), an extracellular matrix glycoprotein, is crucial to cell-migration, proliferation, apoptosis and remodeling of tissues, with a potential role in pathobiology of pulmonary hypertension. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are crucial to the integrity of the extracellular matrix. TN-C and MMPs are counter-regulatory molecules, which influence the vascular integrity through modulations of elastin. We have a murine model of pulmonary hypoplasia with coexistent diaphragmatic hernia, vascular abnormalities and excessive arterial smooth muscle cell (SMC) proliferation.</p><p><strong>Objectives: </strong>Our objective was to investigate modulations of TN-C and MMPs in hypoplastic lungs and their possible contribution to the observed pulmonary vascular abnormalities.</p><p><strong>Methods: </strong>We addressed our objectives by pursing immunoblotting and immunohistochemistry and zymography/reverse zymography to assess the alterations in activities of MMPs and their inhibitors.</p><p><strong>Results: </strong>We observed significant down-regulation of MMP-9 activity in hypoplastic lungs at the later fetal developmental stages, whereas MMP-2 activity assessed by gelatin zymography remained unaltered. Reverse zymography revealed up-regulation of activities of TIMP-1, -2, -3 and -4 in hypoplastic lungs during later fetal development, with pronounced increases in TIMP-3 and -4 activities. Furthermore, immunoblot analyses and immunohistochemistry revealed that TN-C protein was down-regulated in developing hypoplastic lungs, compared to normal lungs.</p><p><strong>Conclusions: </strong>(1)TN-C is known to inhibit vascular SMC proliferation. But, decrease in TN-C in hypoplastic lungs may support the observed arterial SMC proliferation. (2) Our studies showed that in hypoplastic lungs the SMC apoptosis is not affected, thus suggesting that SMC proliferation and apoptosis may be two separate processes in pulmonary hypoplasia with coexistent diaphragmatic hernia. Together, our data showed an imbalance in the extracellular matrix proteins, which may contribute to the pulmonary vascular abnormalities.</p>","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"90 3","pages":"185-96"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000093308","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26022760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Quantitative measurement of monocyte HLA-DR expression in the identification of early-onset neonatal infection. 单核细胞HLA-DR表达在早期新生儿感染鉴定中的定量测定。
Pub Date : 2006-01-01 Epub Date: 2005-09-12 DOI: 10.1159/000088288
Pak Cheung Ng, Geng Li, Kit Man Chui, Winnie Chiu Wing Chu, Karen Li, Raymond Pui On Wong, Tai Fai Fok

Background: This study aimed to evaluate the diagnostic utilities of monocyte HLA-DR as an infection marker in the identification of early-onset clinical infection and pneumonia in newborn infants.

Methods: Term newborns in whom infection was suspected when they were <72 h of age were eligible for enrollment in the study. C-reactive protein (CRP), monocyte HLA-DR and neutrophil CD64 expressions were quantitatively measured at the time of sepsis evaluation (0 h) and 24 h afterwards by flow cytometry and standard laboratory method.

Results: A total of 288 infants with suspected sepsis were investigated, and 93 were found to be clinically infected. There were no significant differences in monocyte HLA-DR expression between the infected, non-infected and control groups at 0 h (median (interquartile range): 13,986 (10,994-18,544), 14,234 (12,045-17,474) and 18,441 (14,250-21,537) antibody phycoerythrin (PE) molecules bound/cell), and between infected and non-infected infants at 24 h (median (interquartile range): 17,772 (12,933-25,167) and 19,406 (14,885-24,225) antibody PE molecules bound/cell). The areas under the receiver operating characteristics (ROC) curves for HLA-DR, CD64 and CRP were 0.52-0.54, 0.88-0.94 and 0.75-0.77, respectively. We were unable to determine an optimal cutoff value for HLA-DR, as the diagnostic utilities of any cutoff point on the ROC curves were unable to satisfy the criteria (i.e. sensitivity and specificity >or=80%) for consideration as an useful diagnostic marker of infection.

Conclusions: Our findings did not support the use of monocyte HLA-DR alone or in combination with other infection markers in the diagnosis of early-onset clinical infection and pneumonia in term newborns.

背景:本研究旨在评估单核细胞HLA-DR作为一种感染标志物在新生儿早发性临床感染和肺炎诊断中的应用价值。结果:共调查疑似脓毒症患儿288例,其中临床感染93例。感染、非感染和对照组之间单核细胞HLA-DR表达在0小时(中位数(四分位数范围):13,986(10,994-18,544)、14,234(12,045-17,474)和18,441(14,250-21,537)抗体藻红蛋白(PE)分子结合/细胞)以及感染和非感染婴儿之间24小时(中位数(四分位数范围):17,772(12,933-25,167)和19,406(14,885-24,225)抗体PE分子结合/细胞)无显著差异。HLA-DR、CD64、CRP的受试者工作特征曲线下面积分别为0.52 ~ 0.54、0.88 ~ 0.94、0.75 ~ 0.77。我们无法确定HLA-DR的最佳截断值,因为ROC曲线上任何截断点的诊断效用都不能满足标准(即灵敏度和特异性>或=80%),不能作为有用的感染诊断标志物。结论:我们的研究结果不支持单独使用单核细胞HLA-DR或与其他感染标志物联合用于足月新生儿早发性临床感染和肺炎的诊断。
{"title":"Quantitative measurement of monocyte HLA-DR expression in the identification of early-onset neonatal infection.","authors":"Pak Cheung Ng,&nbsp;Geng Li,&nbsp;Kit Man Chui,&nbsp;Winnie Chiu Wing Chu,&nbsp;Karen Li,&nbsp;Raymond Pui On Wong,&nbsp;Tai Fai Fok","doi":"10.1159/000088288","DOIUrl":"https://doi.org/10.1159/000088288","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the diagnostic utilities of monocyte HLA-DR as an infection marker in the identification of early-onset clinical infection and pneumonia in newborn infants.</p><p><strong>Methods: </strong>Term newborns in whom infection was suspected when they were <72 h of age were eligible for enrollment in the study. C-reactive protein (CRP), monocyte HLA-DR and neutrophil CD64 expressions were quantitatively measured at the time of sepsis evaluation (0 h) and 24 h afterwards by flow cytometry and standard laboratory method.</p><p><strong>Results: </strong>A total of 288 infants with suspected sepsis were investigated, and 93 were found to be clinically infected. There were no significant differences in monocyte HLA-DR expression between the infected, non-infected and control groups at 0 h (median (interquartile range): 13,986 (10,994-18,544), 14,234 (12,045-17,474) and 18,441 (14,250-21,537) antibody phycoerythrin (PE) molecules bound/cell), and between infected and non-infected infants at 24 h (median (interquartile range): 17,772 (12,933-25,167) and 19,406 (14,885-24,225) antibody PE molecules bound/cell). The areas under the receiver operating characteristics (ROC) curves for HLA-DR, CD64 and CRP were 0.52-0.54, 0.88-0.94 and 0.75-0.77, respectively. We were unable to determine an optimal cutoff value for HLA-DR, as the diagnostic utilities of any cutoff point on the ROC curves were unable to satisfy the criteria (i.e. sensitivity and specificity >or=80%) for consideration as an useful diagnostic marker of infection.</p><p><strong>Conclusions: </strong>Our findings did not support the use of monocyte HLA-DR alone or in combination with other infection markers in the diagnosis of early-onset clinical infection and pneumonia in term newborns.</p>","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"89 2","pages":"75-81"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000088288","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25005544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 42
Effects of oral administration of insulin-like growth factor-I on circulating concentration of insulin-like growth factor-I and growth of internal organs in weanling mice. 口服胰岛素样生长因子- 1对断奶小鼠循环胰岛素样生长因子- 1浓度及内脏生长的影响。
Pub Date : 2006-01-01 Epub Date: 2005-11-17 DOI: 10.1159/000089796
W K Kim, Y H Ryu, D S Seo, C Y Lee, Y Ko

Insulin-like growth factor (IGF)-I is a polypeptide that mediates the growth-promoting action of growth hormone in postnatal animals. The present study was conducted to examine whether orally administered IGF-I would be absorbed into the general circulation and also whether ingested IGF-I would enhance the growth of whole body as well as internal organs, and tissues in 3-week-old ICR-strain female weanling mice. In experiment (Exp) 1, a total of 70 mice received IGF-I orally at 1 microg.g-1 in 0.2-ml PBS or the vehicle alone. Concentrations of IGF-I and glucose in heart blood were measured after killing 5 animals in each group every fourth hour during a 24-hour period. In Exp 2, a total of 40 mice received oral IGF-I administration at 1 microg.g-1 or vehicle every third day beginning from day 0 for a 13-day period. Half the animals were killed at day 7 and the other half at day 13. Weights of whole body and organs/tissues (small intestine, liver, thigh muscle, and brain) were measured every day and at slaughter, respectively. In Exp 1, following the oral IGF-I administration, serum IGF-I concentration increased at hour 4 (p<0.01) and returned to the hour 0 level by hour 8, whereas glucose concentration was lowest at hour 4 and returned to the hour 0 level by hour 16. In the PBS-fed group, neither IGF-I nor glucose concentration changed during the 24-hour period. In Exp 2, weight of small intestine increased (p<0.05) in response to the oral IGF-I, whereas weights of liver and thigh muscle of the IGF-I-fed group were greater (p<0.01) and tended to be greater (p=0.06), respectively, than those of the PBS-fed only at day 13. However, brain weight and serum concentrations of IGF-I and IGF-II were not affected by oral IGF-I administration. Results suggest that although orally administered IGF-I mainly acts at the intestine, a portion of ingested IGF-I is absorbed into the general circulation to enhance the growth of selective organs/tissues in weanling mice.

胰岛素样生长因子(IGF)- 1是一种多肽,可介导出生后动物生长激素的促生长作用。本研究旨在研究口服IGF-I是否会被吸收到全身循环中,以及摄入IGF-I是否会促进3周龄icr系雌性断奶小鼠的全身、内脏和组织的生长。在实验(Exp) 1中,共70只小鼠口服1 μ g IGF-I。g-1在0.2 ml PBS或单独的车辆中。24小时内,每隔4小时处死5只动物,测定各组心脏血液中igf - 1和葡萄糖的浓度。在实验2中,共有40只小鼠口服1微克IGF-I。G-1或车辆,从第0天开始,每三天一次,为期13天。第7天处死一半动物,第13天处死另一半动物。每天和屠宰时分别测定全体和各器官/组织(小肠、肝脏、大腿肌和脑)的重量。在实验1中,口服IGF-I后,血清IGF-I浓度在第4小时升高(p
{"title":"Effects of oral administration of insulin-like growth factor-I on circulating concentration of insulin-like growth factor-I and growth of internal organs in weanling mice.","authors":"W K Kim,&nbsp;Y H Ryu,&nbsp;D S Seo,&nbsp;C Y Lee,&nbsp;Y Ko","doi":"10.1159/000089796","DOIUrl":"https://doi.org/10.1159/000089796","url":null,"abstract":"<p><p>Insulin-like growth factor (IGF)-I is a polypeptide that mediates the growth-promoting action of growth hormone in postnatal animals. The present study was conducted to examine whether orally administered IGF-I would be absorbed into the general circulation and also whether ingested IGF-I would enhance the growth of whole body as well as internal organs, and tissues in 3-week-old ICR-strain female weanling mice. In experiment (Exp) 1, a total of 70 mice received IGF-I orally at 1 microg.g-1 in 0.2-ml PBS or the vehicle alone. Concentrations of IGF-I and glucose in heart blood were measured after killing 5 animals in each group every fourth hour during a 24-hour period. In Exp 2, a total of 40 mice received oral IGF-I administration at 1 microg.g-1 or vehicle every third day beginning from day 0 for a 13-day period. Half the animals were killed at day 7 and the other half at day 13. Weights of whole body and organs/tissues (small intestine, liver, thigh muscle, and brain) were measured every day and at slaughter, respectively. In Exp 1, following the oral IGF-I administration, serum IGF-I concentration increased at hour 4 (p<0.01) and returned to the hour 0 level by hour 8, whereas glucose concentration was lowest at hour 4 and returned to the hour 0 level by hour 16. In the PBS-fed group, neither IGF-I nor glucose concentration changed during the 24-hour period. In Exp 2, weight of small intestine increased (p<0.05) in response to the oral IGF-I, whereas weights of liver and thigh muscle of the IGF-I-fed group were greater (p<0.01) and tended to be greater (p=0.06), respectively, than those of the PBS-fed only at day 13. However, brain weight and serum concentrations of IGF-I and IGF-II were not affected by oral IGF-I administration. Results suggest that although orally administered IGF-I mainly acts at the intestine, a portion of ingested IGF-I is absorbed into the general circulation to enhance the growth of selective organs/tissues in weanling mice.</p>","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"89 3","pages":"199-204"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000089796","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25707306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Normal serum alanine concentration differentiates transient neonatal lactic acidemia from an inborn error of energy metabolism. 正常血清丙氨酸浓度可区分短暂性新生儿乳酸血症和先天性能量代谢错误。
Pub Date : 2006-01-01 Epub Date: 2006-05-29 DOI: 10.1159/000093590
Eva Morava, Marije Hogeveen, Maaike De Vries, Wim Ruitenbeek, Willem-Pieter de Boode, Jan Smeitink

Background: Elevated blood lactate levels are common in the critically ill neonate; however, sometimes they are difficult to interpret. Persistent or recurrent lactic acidemia might point to an inborn error of metabolism, like disturbances of the oxidative phosphorylation. Chronic lactic acidemia results in increased serum alanine levels. Serum alanine levels in newborns with transient lactic acidemia have not yet been studied.

Objective: We designed a pilot study to evaluate the use of serum alanine levels as an additional metabolic marker to differentiate the transient effect of circulatory failure from a possible mitochondrial dysfunction.

Methods: We prospectively evaluated 10 newborns with transient lactic acidemia after mild dysoxia, and 10 newborns with recurrent lactic acidemia consecutively diagnosed with a disorder in oxidative phosphorylation.

Results: No significant serum alanine level elevation was found in transient lactic acidemia. Increased serum alanine was a sensitive marker in mitochondrial dysfunction.

Conclusions: We propose to measure the serum alanine level in hypotonic newborns with lactic acidemia to facilitate the decision making in further diagnostics and management.

背景:血乳酸水平升高在危重新生儿中很常见;然而,有时它们很难解释。持续性或复发性乳酸血症可能指向先天性代谢错误,如氧化磷酸化紊乱。慢性乳酸血症导致血清丙氨酸水平升高。新生儿短暂性乳酸血症的血清丙氨酸水平尚未研究。目的:我们设计了一项初步研究,以评估血清丙氨酸水平作为一种额外的代谢标志物,以区分循环衰竭的短暂影响和可能的线粒体功能障碍。方法:对10例轻度缺氧后出现短暂性乳酸血症的新生儿和10例连续诊断为氧化磷酸化障碍的复发性乳酸血症新生儿进行前瞻性评估。结果:短暂性乳酸血症患者血清丙氨酸水平未见明显升高。血清丙氨酸升高是线粒体功能障碍的敏感标志物。结论:我们建议在低渗新生儿乳酸血症中检测血清丙氨酸水平,以便于进一步诊断和治疗决策。
{"title":"Normal serum alanine concentration differentiates transient neonatal lactic acidemia from an inborn error of energy metabolism.","authors":"Eva Morava,&nbsp;Marije Hogeveen,&nbsp;Maaike De Vries,&nbsp;Wim Ruitenbeek,&nbsp;Willem-Pieter de Boode,&nbsp;Jan Smeitink","doi":"10.1159/000093590","DOIUrl":"https://doi.org/10.1159/000093590","url":null,"abstract":"<p><strong>Background: </strong>Elevated blood lactate levels are common in the critically ill neonate; however, sometimes they are difficult to interpret. Persistent or recurrent lactic acidemia might point to an inborn error of metabolism, like disturbances of the oxidative phosphorylation. Chronic lactic acidemia results in increased serum alanine levels. Serum alanine levels in newborns with transient lactic acidemia have not yet been studied.</p><p><strong>Objective: </strong>We designed a pilot study to evaluate the use of serum alanine levels as an additional metabolic marker to differentiate the transient effect of circulatory failure from a possible mitochondrial dysfunction.</p><p><strong>Methods: </strong>We prospectively evaluated 10 newborns with transient lactic acidemia after mild dysoxia, and 10 newborns with recurrent lactic acidemia consecutively diagnosed with a disorder in oxidative phosphorylation.</p><p><strong>Results: </strong>No significant serum alanine level elevation was found in transient lactic acidemia. Increased serum alanine was a sensitive marker in mitochondrial dysfunction.</p><p><strong>Conclusions: </strong>We propose to measure the serum alanine level in hypotonic newborns with lactic acidemia to facilitate the decision making in further diagnostics and management.</p>","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"90 3","pages":"207-9"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000093590","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26053662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Concerning the article by s. Belda et Al.: screening for retinopathy of prematurity: is it painful? 关于s. Belda等人的文章:筛查早产儿视网膜病变:痛苦吗?
Pub Date : 2006-01-01 Epub Date: 2005-11-15 DOI: 10.1159/000089754
José Figueras-Aloy, J Manuel Rodríguez-Miguélez, M Dolors Salvia-Roiges, Francesc Botet-Mussons
Therefore, we consider that it is as important to relieve the pain as to prevent systemic effects of mydriatics in low-weight infants [3] . The main prophylactic measures are [4] : (1) To use in neonates only the minimum effective concentration of drugs: 2% ophthalmic phenylephrine solution and 0.5% ophthalmic cyclopentolate solution. (2) To reduce systemic absorption of drugs by applying pressure to the lacrimal sac during and for 2 min after instillation. Without lacrimal sac occlusion, approximately 80% of each drop may pass through the nasolacrimal system and be available for rapid systemic absorption by the nasal mucosa. To perform this correctly, two persons are needed: one for applying pressure to the lacrimal sac and the other for instilling the drops. (3) Not to repeat the doses. Usually it is enough to instill one drop of each drug in the eye at least 10 min prior funduscopic procedures, especially if lacrimal sac occlusion is complete. This procedure can be exceptionally repeated 15 min later, but a third dose should never be given. Dear Sir, We read with interest the article by Belda et al. ‘Screening for retinopathy of prematurity: Is it painful?’ [Biol Neonate 2004; 86: 195–200]. We agree with its content but we have a few concerns about some of the information presented in the above referenced article [1] and about practical recommendations that have not been included for neonatologists and nurses taking care of the preterm infants. The objective of the study was to evaluate the ophthalmologic examination side effects in preterm neonates with specially focusing on the occurrence of pain. Gastrointestinal side effects (vomiting and gastric aspirates), minimum oxygen saturation, apneas, and the need for respiratory assistance or intensive care unit admission within 24 h after the examination were assessed. These late clinical side effects are probably not due to pain but to the instillation of mydriatics, as the same authors refer to in the Discussion. These changes on physiologic variables may be life-threatening and can produce, although rarely, a cardiorespiratory arrest [2] . Published online: November 15, 2005
{"title":"Concerning the article by s. Belda et Al.: screening for retinopathy of prematurity: is it painful?","authors":"José Figueras-Aloy,&nbsp;J Manuel Rodríguez-Miguélez,&nbsp;M Dolors Salvia-Roiges,&nbsp;Francesc Botet-Mussons","doi":"10.1159/000089754","DOIUrl":"https://doi.org/10.1159/000089754","url":null,"abstract":"Therefore, we consider that it is as important to relieve the pain as to prevent systemic effects of mydriatics in low-weight infants [3] . The main prophylactic measures are [4] : (1) To use in neonates only the minimum effective concentration of drugs: 2% ophthalmic phenylephrine solution and 0.5% ophthalmic cyclopentolate solution. (2) To reduce systemic absorption of drugs by applying pressure to the lacrimal sac during and for 2 min after instillation. Without lacrimal sac occlusion, approximately 80% of each drop may pass through the nasolacrimal system and be available for rapid systemic absorption by the nasal mucosa. To perform this correctly, two persons are needed: one for applying pressure to the lacrimal sac and the other for instilling the drops. (3) Not to repeat the doses. Usually it is enough to instill one drop of each drug in the eye at least 10 min prior funduscopic procedures, especially if lacrimal sac occlusion is complete. This procedure can be exceptionally repeated 15 min later, but a third dose should never be given. Dear Sir, We read with interest the article by Belda et al. ‘Screening for retinopathy of prematurity: Is it painful?’ [Biol Neonate 2004; 86: 195–200]. We agree with its content but we have a few concerns about some of the information presented in the above referenced article [1] and about practical recommendations that have not been included for neonatologists and nurses taking care of the preterm infants. The objective of the study was to evaluate the ophthalmologic examination side effects in preterm neonates with specially focusing on the occurrence of pain. Gastrointestinal side effects (vomiting and gastric aspirates), minimum oxygen saturation, apneas, and the need for respiratory assistance or intensive care unit admission within 24 h after the examination were assessed. These late clinical side effects are probably not due to pain but to the instillation of mydriatics, as the same authors refer to in the Discussion. These changes on physiologic variables may be life-threatening and can produce, although rarely, a cardiorespiratory arrest [2] . Published online: November 15, 2005","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"89 3","pages":"197; author reply 198"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000089754","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25711495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Can cerebrospinal fluid uric acid levels differentiate intraventricular hemorrhage from traumatic tap? 脑脊液尿酸水平能区分脑室内出血与外伤性脑溢血吗?
Pub Date : 2006-01-01 Epub Date: 2006-06-29 DOI: 10.1159/000094319
Didem Aliefendioğlu, Tuğba Gürsoy, K Mutlu Hayran, Ayşe Tana Aslan

Objective: To measure blood and cerebrospinal fluid (CSF) uric acid (UA) levels of neonates with intraventricular hemorrhage (IVH), and to examine whether or not UA can be used to differentiate traumatic tap from IVH.

Material and methods: The control group (n = 19, group I) consisted of neonates presenting with signs requiring analysis of CSF but whose CSF indices proved to be normal. Traumatic taps (n = 15, group II) were mimicked by adding 2 drops of homologous blood to normal CSF samples. The IVH group (n = 21, group III) consisted of neonates who had been diagnosed by cranial ultrasonography or computed tomography scans. Data are presented as median (range).

Results: There was no significant difference between groups with respect to serum UA levels. While no significant difference was observed between CSF UA levels of the control [0.6 (0.1-1.8) mg/dl] and traumatic tap group [0.5 (0.3-1.1) mg/dl], the IVH group [1.6 (0.7-6.9) mg/dl] was found to have significantly higher CSF UA levels than groups I and II. Furthermore, although there were significant correlations between serum and CSF UA levels in the control and traumatic tap groups, no correlation was observed in the IVH group.

Conclusion: CSF UA levels are increased in neonates with IVH and they may be used to differentiate a real hemorrhage from a traumatic tap.

目的:测定新生儿脑室内出血(IVH)的血、脑脊液尿酸(UA)水平,探讨UA是否可作为外伤性脑室内出血与IVH的鉴别指标。材料与方法:对照组(n = 19,第一组)为有脑脊液分析体征但脑脊液指标正常的新生儿。在正常脑脊液样本中加入2滴同源血,模拟创伤性抽血(n = 15, II组)。IVH组(n = 21, III组)由经颅超声或计算机断层扫描诊断的新生儿组成。数据以中位数(范围)表示。结果:两组患者血清UA水平差异无统计学意义。对照组[0.6 (0.1-1.8)mg/dl]和外伤组[0.5 (0.3-1.1)mg/dl]的脑脊液UA水平无显著差异,而IVH组[1.6 (0.7-6.9)mg/dl]的脑脊液UA水平明显高于I组和II组。此外,尽管在对照组和创伤性tap组中血清和CSF UA水平之间存在显著相关性,但在IVH组中未观察到相关性。结论:脑脊液UA水平在IVH新生儿中升高,可用于区分真正出血与外伤性出血。
{"title":"Can cerebrospinal fluid uric acid levels differentiate intraventricular hemorrhage from traumatic tap?","authors":"Didem Aliefendioğlu,&nbsp;Tuğba Gürsoy,&nbsp;K Mutlu Hayran,&nbsp;Ayşe Tana Aslan","doi":"10.1159/000094319","DOIUrl":"https://doi.org/10.1159/000094319","url":null,"abstract":"<p><strong>Objective: </strong>To measure blood and cerebrospinal fluid (CSF) uric acid (UA) levels of neonates with intraventricular hemorrhage (IVH), and to examine whether or not UA can be used to differentiate traumatic tap from IVH.</p><p><strong>Material and methods: </strong>The control group (n = 19, group I) consisted of neonates presenting with signs requiring analysis of CSF but whose CSF indices proved to be normal. Traumatic taps (n = 15, group II) were mimicked by adding 2 drops of homologous blood to normal CSF samples. The IVH group (n = 21, group III) consisted of neonates who had been diagnosed by cranial ultrasonography or computed tomography scans. Data are presented as median (range).</p><p><strong>Results: </strong>There was no significant difference between groups with respect to serum UA levels. While no significant difference was observed between CSF UA levels of the control [0.6 (0.1-1.8) mg/dl] and traumatic tap group [0.5 (0.3-1.1) mg/dl], the IVH group [1.6 (0.7-6.9) mg/dl] was found to have significantly higher CSF UA levels than groups I and II. Furthermore, although there were significant correlations between serum and CSF UA levels in the control and traumatic tap groups, no correlation was observed in the IVH group.</p><p><strong>Conclusion: </strong>CSF UA levels are increased in neonates with IVH and they may be used to differentiate a real hemorrhage from a traumatic tap.</p>","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"90 4","pages":"268-72"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000094319","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26119476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Partial liquid ventilation with low-dose perfluorochemical and high-frequency oscillation improves oxygenation and lung compliance in a rabbit model of surfactant depletion. 低剂量全氟化学和高频振荡部分液体通气改善表面活性剂耗竭兔模型的氧合和肺顺应性。
Pub Date : 2006-01-01 Epub Date: 2005-10-10 DOI: 10.1159/000088874
Takashi Wakabayashi, Masanori Tamura, Tomohiko Nakamura

Background: Partial liquid ventilation (PLV) with perfluorochemical (PFC) has been advocated as a new therapy for acute respiratory distress syndrome in both clinical and animal studies, meconium aspiration syndrome, and RDS. PFC is referred to as liquid PEEP because it gets distributed to the most gravity-dependent regions of the lung due to its density. High-frequency oscillation (HFO) has been shown to prevent both acute and chronic lung injury in the management of very low birth weight infants with RDS, with gentle ventilation approach. Specifically, HFO with aggressive and adequate lung volume recruitment has been shown to reduce the incidence of chronic lung disease in very low birth weight infants. We hypothesized that PLV along with HFO might be effective in ARDS in an adult rabbit model.

Objectives: To examine the efficiency of low-dose PLV with with HFO on pulmonary gas exchange and lung compliance in a surfactant-depleted rabbit model.

Methods: After induction of severe lung injury by repeated saline lung lavage, 19 adult white Japanese rabbits were randomized into two groups that received PLV with HFO (n=9) or HFO gas ventilation (n=10). Physiological and blood gas data were compared between the two groups by analysis of variance.

Results: The HFO-PLV group showed improved total lung compliance with maintenance of significantly lower mean airway pressure as compared with the HFO-GAS group so as to keep SpO2>90%.

Conclusions: The addition of a low dose of PFC with HFO was effective in achieving adequate oxygenation, with a reduction in further lung injury in neonates.

背景:全氟化学部分液体通气(PLV)作为一种治疗急性呼吸窘迫综合征、胎粪吸入综合征和RDS的新方法在临床和动物研究中都得到了推广。PFC被称为液体PEEP,因为它的密度会分布到肺中最依赖重力的区域。高频振荡(HFO)已被证明可以预防极低出生体重婴儿RDS的急性和慢性肺损伤,采用温和的通气方法。具体而言,积极和充分的肺容量补充的HFO已被证明可以减少极低出生体重婴儿慢性肺病的发病率。我们假设PLV和HFO可能对成年兔急性呼吸窘迫综合征模型有效。目的:观察低剂量PLV与HFO对表面活性剂缺失家兔肺气体交换和肺顺应性的影响。方法:将19只成年大白兔经反复生理盐水肺灌洗诱导严重肺损伤后,随机分为两组,分别给予PLV + HFO (n=9)和HFO气体通气(n=10)。采用方差分析比较两组患者的生理、血气数据。结果:与HFO-GAS组相比,HFO-PLV组肺总顺应性得到改善,平均气道压力维持明显降低,SpO2保持>90%。结论:添加低剂量的PFC和HFO可以有效地实现充足的氧合,并减少新生儿进一步的肺损伤。
{"title":"Partial liquid ventilation with low-dose perfluorochemical and high-frequency oscillation improves oxygenation and lung compliance in a rabbit model of surfactant depletion.","authors":"Takashi Wakabayashi,&nbsp;Masanori Tamura,&nbsp;Tomohiko Nakamura","doi":"10.1159/000088874","DOIUrl":"https://doi.org/10.1159/000088874","url":null,"abstract":"<p><strong>Background: </strong>Partial liquid ventilation (PLV) with perfluorochemical (PFC) has been advocated as a new therapy for acute respiratory distress syndrome in both clinical and animal studies, meconium aspiration syndrome, and RDS. PFC is referred to as liquid PEEP because it gets distributed to the most gravity-dependent regions of the lung due to its density. High-frequency oscillation (HFO) has been shown to prevent both acute and chronic lung injury in the management of very low birth weight infants with RDS, with gentle ventilation approach. Specifically, HFO with aggressive and adequate lung volume recruitment has been shown to reduce the incidence of chronic lung disease in very low birth weight infants. We hypothesized that PLV along with HFO might be effective in ARDS in an adult rabbit model.</p><p><strong>Objectives: </strong>To examine the efficiency of low-dose PLV with with HFO on pulmonary gas exchange and lung compliance in a surfactant-depleted rabbit model.</p><p><strong>Methods: </strong>After induction of severe lung injury by repeated saline lung lavage, 19 adult white Japanese rabbits were randomized into two groups that received PLV with HFO (n=9) or HFO gas ventilation (n=10). Physiological and blood gas data were compared between the two groups by analysis of variance.</p><p><strong>Results: </strong>The HFO-PLV group showed improved total lung compliance with maintenance of significantly lower mean airway pressure as compared with the HFO-GAS group so as to keep SpO2>90%.</p><p><strong>Conclusions: </strong>The addition of a low dose of PFC with HFO was effective in achieving adequate oxygenation, with a reduction in further lung injury in neonates.</p>","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"89 3","pages":"177-82"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000088874","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25631005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Surfactant therapy: present and future perspectives. Proceedings of the 21st International Workshop on Surfactant Replacement. June 1-4, 2006. Oslo, Norway. 表面活性剂治疗:现状与未来展望。第21届表面活性剂替代国际研讨会论文集。2006年6月1日至4日。挪威奥斯陆。
Pub Date : 2006-01-01 Epub Date: 2005-12-06 DOI: 10.1159/000090115
Biol Neonate 2006;89:257–259 258 10 Revak S, Merritt TA, Cochrane CG: Effi cacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996; 39: 715–724. 11 Walther FJ, Gordon LM, Zassadzinski JA, Sherman MA, Waring AJ: Surfactant protein B and C analogues. Mol Genet Metab 2000; 71: 342–351. 12 Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane C: Comparative effects of some serum components and proteolytic products of fi brinogen on surface tension-lowering abilities of beractant and a synthetic containing surfactant KL 4 . Pediatr Res 1996; 39: 540– 545. 13 Nutt M, Patel N, Rairkart M, Niven R: Comparison of the novel lung surfactant Surfaxin (lucinactant) with currently available commercial products. Pediatr Res 2004; 50: 466A. 14 Christofi dou-Solomidou M, Argyris E, Bohen A, Stephens S, Niven R, Segal R: Novel lung surfactant (KL 4 -surfactant) prevents hyperoxic lung injury in mice and decreases neutrophil transmigration in vitro. PAS 2005: 57: 2497. 15 Cochrane CG, Revak SD, Merritt TA, et al: The effi cacy and safety of KL 4 -surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404–410. 16 Moya FR, Gadzinowski J, Bancalari E, et al: A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018–1029. 17 Sinha SK, Lacaze-Masmonteil T, Soler AV, et al: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030–1038.
{"title":"Surfactant therapy: present and future perspectives. Proceedings of the 21st International Workshop on Surfactant Replacement. June 1-4, 2006. Oslo, Norway.","authors":"","doi":"10.1159/000090115","DOIUrl":"https://doi.org/10.1159/000090115","url":null,"abstract":"Biol Neonate 2006;89:257–259 258 10 Revak S, Merritt TA, Cochrane CG: Effi cacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 1996; 39: 715–724. 11 Walther FJ, Gordon LM, Zassadzinski JA, Sherman MA, Waring AJ: Surfactant protein B and C analogues. Mol Genet Metab 2000; 71: 342–351. 12 Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane C: Comparative effects of some serum components and proteolytic products of fi brinogen on surface tension-lowering abilities of beractant and a synthetic containing surfactant KL 4 . Pediatr Res 1996; 39: 540– 545. 13 Nutt M, Patel N, Rairkart M, Niven R: Comparison of the novel lung surfactant Surfaxin (lucinactant) with currently available commercial products. Pediatr Res 2004; 50: 466A. 14 Christofi dou-Solomidou M, Argyris E, Bohen A, Stephens S, Niven R, Segal R: Novel lung surfactant (KL 4 -surfactant) prevents hyperoxic lung injury in mice and decreases neutrophil transmigration in vitro. PAS 2005: 57: 2497. 15 Cochrane CG, Revak SD, Merritt TA, et al: The effi cacy and safety of KL 4 -surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404–410. 16 Moya FR, Gadzinowski J, Bancalari E, et al: A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018–1029. 17 Sinha SK, Lacaze-Masmonteil T, Soler AV, et al: A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030–1038.","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"89 4","pages":"282-351"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000090115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25733847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stopping a randomized trial early: from protocol to publication. Commentary to Thome at al.: outcome of extremely preterm infants randomized at birth to different PaCO2 targets during the first seven days of life (Biol Neonate 2006;90:218-225). 提前停止随机试验:从方案到发表。对家庭的评论:出生时随机分配到生命前7天不同PaCO2目标的极早产儿的结局(Biol Neonate 2006;90:218-225)。
Pub Date : 2006-01-01 Epub Date: 2006-04-19 DOI: 10.1159/000092724
Pollyanna Hardy, Felicity Clemens
even reverse itself, and so fi xed stopping rules dictated by predetermined signifi cance levels for differences in outcome are increasingly discouraged [3] . Additional information such as the medical plausibility of the difference, ethical considerations both for the trial participants and for the wider target population, evidence from other relevant trials and the nature of the disease under consideration may also be important [2, 4–6] . The decision to stop a trial for harm can also be based on adverse events, although attribution of the cause of an adverse event may be diffi cult [3] . There is less guidance available on when and how trials should be stopped for futility. The 2005 DAMOCLES study [3] highlights a recognition in the literature that termination of a trial may be recommended where it is considered that there is no longer a reasonable chance of accumulating suffi cient evidence against the null hypothesis (usually due to poor recruitment or to external information becoming available [7] ). However, it is unclear whether trials should be stopped on these grounds [3, 4] . Another reason for stopping for futility is that the trial is unlikely to come to a sound conclusion [3] . This is illustrated in the trial by Thome et al. The diffi culty with this trial was that, at the time of the interim analysis, the majority of the patients randomized to the active arm (minimal ventilation to achieve higher PaCO 2 ) had not An important, often neglected element to planning a clinical trial is to consider the possibility of stopping the trial early, before either recruitment or follow-up is completed. A trial may be stopped for futility, harm or benefi t. A trial that is stopped on the grounds of benefi t is one that early on identifi es important treatment effects unlikely to be due to chance. A trial stopped for harm provides evidence that the treatment under investigation is unsafe for trial subjects. A trial stopped for futility requires a decision that the trial would not provide suffi ciently useful information to warrant continuation. Stopping a trial early is always a diffi cult decision to make and consideration must be given to who will be making these decisions and on what grounds they will be made. This issue of Biology in the Neonate publishes a trial by Thome et al. investigating the use of increased PaCO 2 targets on outcomes in extremely preterm neonates. It appears that this trial was stopped for futility on the grounds that the increased target levels of PaCO 2 were not being reached in the active arm of the trial. Guidance for stopping a trial for benefi t or harm is well documented [1] although approaches remain controversial. Statistical methods exist and may contribute to deciding whether the observed data imply that benefi t is very likely or, in the case of stopping for harm, very unlikely, or that the new treatment is harmful [2] . An early trend in the data under consideration may fl uctuate and Published online: Apr
{"title":"Stopping a randomized trial early: from protocol to publication. Commentary to Thome at al.: outcome of extremely preterm infants randomized at birth to different PaCO2 targets during the first seven days of life (Biol Neonate 2006;90:218-225).","authors":"Pollyanna Hardy,&nbsp;Felicity Clemens","doi":"10.1159/000092724","DOIUrl":"https://doi.org/10.1159/000092724","url":null,"abstract":"even reverse itself, and so fi xed stopping rules dictated by predetermined signifi cance levels for differences in outcome are increasingly discouraged [3] . Additional information such as the medical plausibility of the difference, ethical considerations both for the trial participants and for the wider target population, evidence from other relevant trials and the nature of the disease under consideration may also be important [2, 4–6] . The decision to stop a trial for harm can also be based on adverse events, although attribution of the cause of an adverse event may be diffi cult [3] . There is less guidance available on when and how trials should be stopped for futility. The 2005 DAMOCLES study [3] highlights a recognition in the literature that termination of a trial may be recommended where it is considered that there is no longer a reasonable chance of accumulating suffi cient evidence against the null hypothesis (usually due to poor recruitment or to external information becoming available [7] ). However, it is unclear whether trials should be stopped on these grounds [3, 4] . Another reason for stopping for futility is that the trial is unlikely to come to a sound conclusion [3] . This is illustrated in the trial by Thome et al. The diffi culty with this trial was that, at the time of the interim analysis, the majority of the patients randomized to the active arm (minimal ventilation to achieve higher PaCO 2 ) had not An important, often neglected element to planning a clinical trial is to consider the possibility of stopping the trial early, before either recruitment or follow-up is completed. A trial may be stopped for futility, harm or benefi t. A trial that is stopped on the grounds of benefi t is one that early on identifi es important treatment effects unlikely to be due to chance. A trial stopped for harm provides evidence that the treatment under investigation is unsafe for trial subjects. A trial stopped for futility requires a decision that the trial would not provide suffi ciently useful information to warrant continuation. Stopping a trial early is always a diffi cult decision to make and consideration must be given to who will be making these decisions and on what grounds they will be made. This issue of Biology in the Neonate publishes a trial by Thome et al. investigating the use of increased PaCO 2 targets on outcomes in extremely preterm neonates. It appears that this trial was stopped for futility on the grounds that the increased target levels of PaCO 2 were not being reached in the active arm of the trial. Guidance for stopping a trial for benefi t or harm is well documented [1] although approaches remain controversial. Statistical methods exist and may contribute to deciding whether the observed data imply that benefi t is very likely or, in the case of stopping for harm, very unlikely, or that the new treatment is harmful [2] . An early trend in the data under consideration may fl uctuate and Published online: Apr","PeriodicalId":9091,"journal":{"name":"Biology of the neonate","volume":"90 4","pages":"226-8"},"PeriodicalIF":0.0,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000092724","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25991838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Biology of the neonate
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1